Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

P53 is a critical tumor suppressor gene, activating p53 and its downstream targets to induce apoptosis is a promising way for cancer therapy. However, more than 50% of cancer patients have p53 mutations, which may cause cancer therapy resistance, and the underline mechanism is poorly understood. Her...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Cycle
Autors principals: Huang, Yuan, Liu, Nannan, Liu, Jing, Liu, Yeying, Zhang, Chuchu, Long, Shuaiyu, Luo, Guang, Zhang, Lingling, Zhang, Yingjie
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6927701/
https://ncbi.nlm.nih.gov/pubmed/31726940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2019.1688951
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars